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Abstract
Background—Periodontitis is a novel risk factor for inflammation and cardiovascular disease in
the dialysis population. Limited information about the impact of periodontal therapy in patients
receiving dialysis exists.
Study Design—Randomized, controlled trial to assess feasibility and gather preliminary data.
Setting & Participants—Dialysis patients with moderate/severe chronic periodontitis.
Intervention—Intensive treatment, consisting of scaling and root planing, extraction of hopeless
teeth, and placement of local delivery antibiotics was performed at the baseline visit for treatment
group patients and following study completion for control group patients.
Outcomes—Outcomes were feasibility (screening, recruitment, enrollment, adverse events and
study withdrawal/completion), clinical periodontal parameters [probing depth (PD), clinical
attachment level, bleeding on probing, gingival index (GI), and plaque index] and serum albumin
and interleukin 6 levels at 3 and 6 months postintervention.
© 2012 The National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Corresponding Author: Meggan Wehmeyer; 7500 Cambridge Street, Suite 6470, Houston, TX 77054; tel (830) 388-1124; fax (713)
486-4393; meggan.wehmeyer@gmail.com.
Trial registration: www.ClinicalTrials.gov; study number: NCT00937976.
Financial Disclosure: Dr Offenbacher is on the scientific advisory board for OraPharma Inc. The other authors declare that they have
no other relevant financial interests.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Am J Kidney Dis. Author manuscript; available in PMC 2014 March 01.
Published in final edited form as:













Results—A total of 342 dialysis patients were approached for participation: 53 were randomized,
with 26 participants assigned to immediate treatment and 27 to a control arm for treatment after 6
months. 51 patients completed baseline appointments; 46 were available for 3 month follow up
and 45 were available for 6 month follow up examinations. 43 participants completed all visits. At
3 months, there was a statistically significant improvement for the treatment group compared to
the control group for 3 periodontal parameters: mean PD (p=0.008), extent PD ≥ 4 mm (p=0.02),
and extent GI ≥1 (p=0.01). By 6 months, however, the difference between groups was no longer
present for any variable except PD ≥ 4 mm (p=0.04). There was no significant difference between
the groups for serum albumin or high-sensitivity interleukin 6 at any time point, when adjusted for
body mass index, diabetic status, and plaque index.
Limitations—Small sample size and relatively healthy population. Imbalance in diabetes.
Conclusions—This small trial demonstrates successful cooperation between dentists and
nephrologists and successful recruitment, treatment and retention of dialysis patients with
periodontitis. Larger studies with longer follow up are needed to determine whether treatment can
improve markers of inflammation and morbidity.
Keywords
kidney diseases; hemodialysis; end stage renal disease; periodontal diseases; periodontitis/
complications
Systemic inflammation, common among patients receiving dialysis therapy, is a strong
predictor of morbidity and mortality. Studies have demonstrated abnormal levels of serum
inflammatory biomarkers in 30%–60% of all dialysis patients1–4. Such markers, including
low serum albumin and high C-reactive protein (CRP), are associated with an increased risk
of cardiovascular disease (CVD) and death5, 6.
Periodontitis is a damaging inflammatory process of the dental support structures. Bacteria,
present in oral biofilms at numbers greater than 1010 organisms 7, infiltrate the space created
by periodontitis and elicit local inflammation 8, 9. In susceptible individuals, organisms can
evade local defenses and invade the circulation to induce a systemic inflammatory response,
including the elevation of CRP and interleukin 6 (IL-6)10–12. The association between
periodontal infection and risk for CVD and atherosclerosis are postulated to be mediated
partly through a series of acute phase reactants and inflammatory cytokines13–18.
Recent evidence has demonstrated a high burden of periodontitis among patients with
chronic kidney disease19–23. Studies suggest that among patients receiving hemodialysis, the
presence of severe periodontitis is associated with low levels of serum albumin 24, 25.
Furthermore, two independent cohorts of hemodialysis patients have demonstrated that
severe periodontitis at baseline is associated with an increased risk of CVD-related death
during the follow-up period compared to no disease26, 27.
There is limited information on the effect of treatment for periodontitis in the dialysis
population. Information from such studies could help to reduce periodontitis associated
morbidity 26, 27. As a first step, we conducted a small exploratory study to determine the
feasibility of treating periodontitis among patients receiving dialysis therapy. Our goals
were: (1) to determine the impact of treatment on clinical measures of periodontitis severity;
(2) to determine the impact of periodontal treatment on pre-specified laboratory parameters
(serum albumin and interleukin-6); and (3) to assess recruitment and retention of patients.
We present the findings of a small, randomized, controlled study examining the effect of
periodontal treatment among patients receiving outpatient dialysis.
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Hemodialysis and peritoneal dialysis patients were recruited from clinics within a 25 mile
radius of the University of North Carolina (UNC) from July 2008 through December 2009.
Patients were approached at outpatient dialysis clinics by one of the study authors (MW).
Interested patients were verbally screened, and consent for an intra-oral screening was
obtained for those who met verbal criteria (criteria that did not require an intra-oral
examination). All enrolled subjects met the following inclusion criteria: presence of
moderate/severe periodontitis28 (≥2 teeth with ≥ 6 mm clinical attachment loss and at least 1
site with probing depth > 5 mm), receiving dialysis for at least 3 months, English speaking,
ability and willingness to give written informed consent, age 18–80 years, and presence of
12 or more teeth.
Subjects were excluded for the following reasons: severe co-morbid conditions likely to
affect life expectancy within one year (for example, metastatic cancer); dementia; pregnancy
or lactation; inability to take oral medications; allergy or intolerance to minocycline,
tetracyclines or polyglycolate polymers; allergy to both penicillin and clindamycin; severe
dental caries; pulpal or mucosal disease that would interfere with periodontal therapy; any
condition that would, in the judgment of the clinician or patient’s physician, be a
contraindication to dental treatment; and inability or unwillingness to follow the study
protocol. Written informed consent and HIPAA consent were obtained from all subjects.
The study was approved by the Biomedical Institutional Review Board of the UNC and was
conducted in accordance with the Helsinki Declaration of 1975, revised in 2000.
Subjects were randomized (1:1) to either treatment or control group using a randomized
block design generated by the study statistician using SAS Proc Plan (www.sas.com) and
were assigned sequentially by study staff (blinded, non-examiner). The treatment group
received periodontal therapy following the baseline examination; the control group received
periodontal therapy at the conclusion of the study. Subjects were given appointments for a
baseline visit at the clinical research facility of the dental school in Chapel Hill, NC. Study
appointments occurred on the subjects’ inter-dialysis day with the exception of those
receiving peritoneal dialysis.
Treatment protocol
Periodontal treatment consisted of removal of supra- and subgingival microbial deposits via
scaling and root planing (SRP) under local anesthesia using hand and ultrasonic instruments.
Adjunctive local delivery antimicrobial therapy with controlled-release microsphere-
encapsulated, biodegradable minocycline was administered to all sites with >5 mm probing
depths at the time of SRP and at the 3 and 6 month follow up appointments, thus the term
“intensive therapy.” Any teeth deemed hopeless29 (gross decay, severe bone loss with severe
mobility, abscess, etc.) were extracted at the time of scaling and root planing in the quadrant.
Treatment was done in one or two appointments by one of three trained providers.
All subjects received verbal and written oral hygiene instruction at each visit. Each subject
received instructions and demonstrations in the use of a soft-bristled toothbrush with the
modified Bass technique (wherein a toothbrush is held at a 45-degree angle against teeth and
gumline then used in circular fashion) and the use of floss with the “c-wrap” technique
(wherein floss is wrapped around tooth in a “c” shape).
Treatment group subjects received follow up examinations at 3 and 6 months after
completion of treatment; control group subjects received follow up examinations at 3 and 6
months after baseline and received treatment at the conclusion of the study.
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Examiners were calibrated for accuracy and repeatability against a gold standard. An initial
calibration with all examiners was performed, followed by yearly re-calibrations. Percent
agreement with the gold standard was >90% for probing depth (PD) and clinical attachment
loss measurements (CAL), and Kappa scores were >0.90.
Subject medical histories were reviewed and updated at every appointment. The following
were assessed on all subjects at baseline, 3 months and 6 months. Plaque Index (PI): The
modified Silness and Löe plaque and stain index30 was scored for three facial surfaces
(distofacial, facial, mesiofacial) and the direct lingual surfaces of each tooth. Gingival Index
(GI): The Löe and Silness gingival index31 was scored on three facial surfaces (distofacial,
facial, mesiofacial) and the direct lingual surfaces following a 1-mm subgingival sweep.
Probing Depth (PD): A manual periodontal probe (UNC-15; manufacturer name) was used
to measure PD. PD was measured from the free gingival margin to the base of the pocket,
and was recorded in whole millimeters (rounded down). Clinical Attachment Level (CAL):
CAL was calculated using the formula: probing depth measurement minus gingival margin
to cemento-enamel junction (CEJ) measurement (where a gingival margin coronal to the
CEJ is recorded as a positive number, rounded down to the nearest millimeter). Bleeding on
Probing (BOP): BOP was assessed and recorded after probing measurements and CAL for
each quadrant. PD, CAL, BOP were recorded for six sites per tooth for all teeth present.
A 14-radiograph periapical series was obtained to assess additional pathology. Referrals for
treatment were made as needed.
Serological Parameters
Venous blood (2 vials of 5–7 ml each) was collected under sterile technique. Blood was
processed into serum within 2 hours after collection: whole blood was kept at room
temperature for 30–45 minutes to allow a clot to form, and then centrifuged for 12 minutes
at ≥ 1500 rcf to separate serum. Serum was aliquoted into barcode-labeled microfuge tubes,
frozen at −80°C and stored until analysis. High-sensivity interleukin-6 was assayed by high-
sensitivity enzyme-linked immunofluorescent assay (ELISA; R&D Systems,
www.rndsystems.com) and read out using a SpectraMax M2 from Molecular Devices
(www.moleculardevices.com). Serum albumin was analyzed via colorimetric assay on dry
slides (Ortho Johnson and Johnson, www.orthoclinical.com).
Statistics
A sample size of 25 per treatment group at 6 months follow-up was calculated to provide
80% power to detect statistically significant differences in the mean levels of the primary
outcomes between the two treatments that are as small as 79% of the applicable standard
deviation, using two-sided 0.05 significance tests. The estimated standard deviation of
serum albumin is 0.53, and the minimum detectable difference is 0.42. These power
calculations were based upon a simple two-group comparison of a single outcome variable
at the six month follow-up visit with the independent t-test.
Additional variables considered included age (years), gender (male or female), body mass
index (BMI in kg/m2), diabetic status (diabetic or not), dialysis type (hemodialysis or
peritoneal dialysis), time on dialysis (months), smoking status (current smoker or non-
smoker), and a personal medical history of heart disease (known history or no known
history).
Statistical analysis was performed using SAS (SAS 9.1.3, SAS Institute Inc www.sas.com).
Exploratory univariate data analyses using plots (horizontal bar charts, box plots, and
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normal probability plots) and test statistics were conducted to examine distributions of
periodontitis parameters, co-morbid variables (listed earlier), and outcome variables and to
inspect for outliers and missing data. Outliers (more than two standard deviations from the
mean) were detected and checked for accuracy. Analysis with outliers excluded did not
significantly alter conclusions for any outcome parameter. Analysis included means and
standard deviation for continuous variables and percents for categorical variables. Skewed
variables were analyzed using median and interquartile ranges; comparisons were made
based on the Wilcoxon rank-sum test. Baseline comparisons between treatment groups for
other variables were done using chi-squared tests and t-tests, as appropriate.
A general linear model (GLM) with correlated errors 32 was fit to the baseline and with three
and six month follow-up data for each outcome. An unstructured covariance matrix for
within-subject errors was specified using the repeated statement of SAS Proc MIXED. As
covariates, the model included dummy variables for time (3 months and 6 months with
baseline as the reference), treatment group, and the interaction of time and treatment group.
Model-based estimates of the mean levels of outcomes at each time were produced. The
Kenward-Roger degrees-of-freedom adjustment was used to test the (null) hypotheses of no
treatment differences in mean changes of the outcome relative to baseline at three and six
months, respectively. P-values <0.05 were considered statistically significant.
Results
A total of 342 dialysis patients were approached for participation (Figure 1). Of these, 262
patients (77%) agreed to be screened (Figure 2). Interested subjects were verbally screened
and consent for an intra-oral screening was obtained for those who met verbal criteria. The
most common reasons for exclusion were: presence of less than 12 teeth in the mouth (n=97
[37%]); and age >80 years (n=26 [10%]). Interestingly, only 13 of those screened (5%) were
excluded by probing depth (i.e. they did not have sufficient periodontal disease to qualify).
Other reasons cited for non-participation included “fear of dentists” and “lack of time.” Of
those screened, 68 patients (26%) met all inclusion criteria and agreed to participate. Fifteen
subjects (22%) of those who initially agreed to participate did not attend the baseline
examination. Fifty-three subjects (15% of approached patients) were enrolled and
randomized. Twenty-six subjects were randomized to the periodontal treatment group and
27 subjects were randomized to the control group. Two subjects were randomized, but
withdrew prior to baseline and were excluded from analysis. Full clinical parameters and
serum samples were obtained for 51 subjects at baseline, for 46 subjects at 3 months and for
45 subjects at 6 months. Forty-three subjects completed all study visits. Two subjects (both
in treatment group) missed 3 month follow up only and were not withdrawn. Three subjects
(1 in control group: medical instability; 2 in treatment group: received kidney transplants)
missed the 6 month follow up only and were withdrawn from the study. Three subjects (all
in control group: 1 no-show/lost to follow up, 1 deceased, 1 medical instability) missed both
the 3 and 6 month follow up and were withdrawn from the study. Twenty-eight total adverse
events (13, control group; 15, treatment group) were reported among twenty-three subjects.
Twenty-four events were deemed unrelated (for example: subject diagnosed with
hypothyroidism). Two mild events were probably related (dentinal sensitivity). Two events
were possibly related (increase in probing depth, catheter infection). Ten unrelated events
were classified as severe.
Mean participant age was 53.4 +/− 9.79 (standard deviation [SD]; range, 30–75) years.
Statistically, treatment and control groups did not differ significantly at baseline by any
variable measured (Table 1); however, about half (51%) were diabetic, and the diabetics
were unevenly distributed between control and treatment groups with 62% of diabetics
randomized to the treatment group and 38% randomized to the control group (p=0.07).
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Based on BMI-based definitions,33 Eleven percent of subjects were normal weight (BMI,
18.50–24.99 kg/m2), 47% were overweight (BMI, 25.00–29.99 kg/m2) and 42% were obese
(BMI, ≥30.00 kg/m2). Median time on dialysis was 19 (overall range, 3–176) months. Only
14% were current cigarette smokers. Eighty-five percent were on hemodialysis (versus
peritoneal dialysis). The most common cause of kidney failure was hypertension, followed
by diabetes.
At baseline, the overall mean number of teeth per subject was 23 +/− 5, mean extent (% of
sites) with bleeding on probing was 44% +/− 23% and mean extent plaque score ≥1 was
90% +/− 19%. On average, extent of sites with clinical attachment loss ≥3 was 41% +/−
26%. Seventy five percent had 4 or more sites with ≥5mm probing depth. Mean baseline
serum albumin was 4.13g/dl (standard error [SE], 0.10) for the control group and 4.40g/dl
(SE, 0.10) for the treatment group. Mean high-sensitivity IL-6 was 6.40 pg/ml (SE, 2.35) for
the control group and 8.60 (SE, 2.44) for the treatment group. There were no statistically
significant differences between clinical periodontal parameters or serum markers at baseline.
Figure 3 summarizes the clinical periodontal parameters for control versus treatment group
at baseline, 3 months and 6 months. At 3 months, there was a statistically significant
improvement for the treatment group compared to the control group for three periodontal
parameters (Table 2): mean PD (p=0.008), extent PD ≥4mm (p=0.02), and extent GI ≥1
(p=0.01). There were apparent improvements in two parameters, mean CAL and extent CAL
≥3mm, in the treatment group compared with the control group, but the differences were
nonsignificant (p=0.08 and 0.09, respectively). By 6 months, however, the difference
between groups was no longer present for any variable except extent PD≥4mm (p=0.04).
Adjusting for BMI, diabetic status, and plaque index did not significantly alter results and
these variables were not included in the final model.
General linear models with correlated errors for repeated measures were used for
comparisons of serum parameters between treatment groups. There was no difference
between the groups for serum albumin or high-sensitivity IL-6 at any time point, when
adjusted for BMI, diabetic status, and plaque index (Table 3). No subjects improved from a
serum albumin of <4g/dl to >4g/dl during the course of the study.
Discussion
We successfully completed a randomized controlled study to determine the efficacy of
intensive periodontal treatment in patients with end-stage renal disease. Intensive treatment
statistically significantly improved several measures of periodontal health at 3 months;
however at 6 months only extent PD ≥4mm improvement remained statistically significant.
Intensive treatment was not associated with an improvement in high-sensitivity IL-6 or
serum albumin levels at either 3 or 6 months of follow-up. Interestingly, control subjects
also exhibited some improvement in clinical parameters, potentially attributable to oral
hygiene instruction and their awareness of being observed 34 which may decrease the
observed impact of periodontal therapy.
Limited information about the effect of periodontal therapy on patients receiving renal
dialysis exists. Previous studies in non-dialysis populations have demonstrated that
treatment of periodontitis improves flow-mediated dilation, a marker of endothelial function
and intermediate measure of cardiovascular disease35–37. In fact, a recent randomized,
controlled trial showed a remarkable improvement of 2% in flow-mediated dilation for 6
months after scaling and root planing38. Another recent paper39 demonstrated that treatment
of periodontal disease improved CRP values in the dialysis population. Given these
intervention studies showing benefit, and the preponderance of epidemiological evidence in
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the chronic kidney disease population24, 26, 27, we were surprised by the modest beneficial
effect. Potential explanations of our findings center around four inter-related issues: the
relative healthiness of the participants, a greater proportion of diabetics in the treatment arm,
lack of maintenance therapy, and insufficient power.
Patients enrolled into the study were relatively healthy compared to most individuals
receiving dialysis therapy 40 and to patients in previous observational studies24–27. In fact,
several variables speak to the relative health of this population, including elevated serum
albumin41–44, elevated BMI45–48, and the ability of the patients to attend appointments on
non-dialysis days. Previous observational studies have been non-invasive and examinations
were performed on-site in less than 20 minutes. They did not require additional time or
travel commitment by the participants. In the present study, participants were required to
attend five 1–2 hour appointments at the dental clinic. In this study population, this
requirement likely selected for healthier patients with the time and ability to attend
appointments. The pre-specified requirement of a set number of teeth (12) may have
excluded patients with the most severe periodontitis since fewer teeth may reflect tooth loss
due to extensive disease. Previous epidemiologic studies demonstrating the association of
periodontal disease with low albumin 24, 25 and mortality 26, 27 had less stringent restrictions
for minimum number of teeth.
Despite randomization, 62% of diabetics were assigned to the treatment group while only
38% of diabetics were assigned to the control group. Diabetes and periodontitis have a
complex interrelationship, each affecting the other 49. Diabetes is often referred to as one of
the most important systemic disease risk factors for periodontitis. Reduced wound healing
ability has a profound impact on periodontitis expression as well as on response to
periodontal therapy. This may have dampened observed treatment effects.
Treatment, consisting of one-time scaling and root planing and administration of local
delivery minocycline, may not have been sufficient. The treatment group displayed
statistically significant improvement or an apparent trend for improvement in 5 of the 7
clinical parameters at the 3 month follow up appointment followed by partial relapse in
every parameter at 6 months. While slightly improved, compliance with oral hygiene
instruction in all groups was generally poor, as demonstrated by high plaque scores. Even
following treatment, plaque levels in the treatment group at 3 and 6 months remained higher
(PI range, 86.0%–93%) than is generally considered compatible with health (PI range, 10%–
15%). These findings emphasize the need for regular periodontal maintenance, particularly
given poor oral hygiene among these subjects and their inability to maintain clinical
improvements over time with home care alone.
Studies have demonstrated the critical role of regular maintenance in controlling
periodontitis 50,51. Maintenance typically consists of plaque and calculus removal,
assessment of periodontal and oral health status and oral hygiene evaluation/instruction
performed on an individualized interval (commonly every three months). Improvements in
periodontal health can often be maintained using this approach despite a patient’s own poor
oral hygiene52. Maintenance was not provided in this study, as the goal of this study was to
examine the effect of a single round of scaling and root planing. Given the poor home care
among this population as indicated by high levels of plaque and BOP, subjects would likely
have benefitted from a maintenance program.
Initial power calculations were based on 25 subjects per group, however, by 6 months, only
23 subjects remained in the treatment group and 22 remained in the control group. Post hoc
analysis of our data shows that in our sample, the power of detecting a 0.15 observed
difference in serum albumin is 0.14. Thus, this study did not have adequate power to detect
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differences between the groups in serum albumin; the results of this study serve as
preliminary and feasibility data and provide insight into future study design. Based on our
observations, using the three month high-sensivity IL-6 data and given delta scores for
control and treatment of 0.213 +/− 9.018 and −1.887 +/−9.018, respectively, power at 0.8
results in a necessary sample size of 582 subjects for a full scale trial. Using the six month
IL-6 data and given delta scores of 0.524 +/− 11.033 and −3.186 +/− 11.033, respectively,
power at 0.8 results in a necessary sample size of 280 subjects for a full scale trial.
Given the modest observed effects, we caution against concluding that treatment of
periodontitis may be ineffective. Rather, the findings of this study serve to inform the design
of future trials in this field. Limitations in this trial include small sample size and uneven
distribution of diabetics between the study groups. For future trials, a longer follow up time
may be needed to observe impacts on inflammatory markers. Additionally, given results
from other studies, a broader range of inflammatory markers may present a more complete
profile. With respect to inclusion criteria, restrictions on age range and number of teeth
should be broadened to include participants with age greater than 80 years and with fewer
teeth. Periodontal treatment should be expanded to include maintenance visits every 3
months or less. Given the large number of patients screened for participation, a study with
multiple centers would be preferable to a single center attempt.
In summary, this small trial demonstrates successful cooperation between dentists and
nephrologists and successful recruitment, treatment and retention of dialysis patients with
periodontitis. Treatment of periodontitis in dialysis patients improved clinical measures of
periodontitis severity but did not produce an observable impact on serum markers of
inflammation. Larger studies are needed to examine the effect of treatment on biomarkers
and clinically significant events such as cardiovascular disease morbidity and mortality.
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Status of Screened Subjects and Reasons for Ineligibility (n=262). PD, probing depth.
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Mean (SE) Clinical Measures for Each Time Point by Treatment Group(PD= probing depth,
BOP= bleeding on probing, PI= plaque index, GI= gingival index, CAL= clinical attachment
level) *significant at p≤0.05
Wehmeyer et al. Page 14

























Wehmeyer et al. Page 15
Table 1
Baseline characteristics of control and treatment groups
Characteristic Control Group (n=26) Treatment Group (n=25) p-values*
Sex 0.5
 Male 18 (69%) 15 (60%)
 Female 8 (31%) 10 (40%)
Race 0.6
 African-American 23 (88%) 21 (84%)
 Non-African 3 (12%) 4 (16%)
 American
Smoker 0.9
 Never 14 (54%) 15 (60%)
 Former 8 (31%) 7 (28%)
 Current 4 (15%) 3 (12%)
Heart Disease 0.6
 No 17 (65%) 18 (72%)
 Yes 9 (35%) 7 (28%)
Diabetes 0.07
 No 16 (62%) 9 (36%)
 Yes 10 (38%) 16 (64%)
Age (y) 52.7 (10.6) 54.1 (9.0) 0.6
BMI (kg/m2) 31.9 (6.4) 31.4 (8.3) 0.8
Dialysis Vintage** (mo) 18 (8–89) 22 (10–65) 0.9
Dialysis type 0.6
 Hemodialysis 23 (88%) 21 (84%)
 Peritoneal 3 (12%) 4 (16%)
Note: Unless otherwise indicated, values for categorical variables are given as number (percentage); values for continuous variables as mean +/−
standard deviation or median (interquartile range).
*
Significance tests for comparisons between treatment and control group based on 2-sample t-test for continuous patient characteristics and
Pearson’s chi-square test for categorical patient characteristics. None were statistically significant at p<0.05.
**
Dialysis vintage is a skewed variable; hence median (interquartile ranges) is reported. P-value is based on the Wilcoxon rank-sum test.
BMI, body mass index
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